TrialThyroid : official journal of the American Thyroid Association2024

Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study.

Jaume Capdevila et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.